For how we live.
A Manaus trial found chloroquine alone let 27% of Plasmodium vivax patients relapse by day 42; dihydroartemisinin-piperaquine cut that to 2.4%. Paired with primaquine, both drugs did well.
Two WHO-endorsed shots are now available, but a new analysis argues the harder problem is financing them in the lowest-income, highest-burden countries. Nigerian rollout data shows demand outpacing readiness.
As RTS,S reached more than 2 million children in Ghana, Kenya and Malawi, a WHO-coordinated pilot trained about 6,000 health workers to detect and report side-effects that most rollouts assume can already be caught.
A meta-analysis of 56 trials and 134,424 children finds RTS,S and R21 cut clinical malaria by about a third overall, with efficacy strongest alongside seasonal chemoprevention and waning after 36 months.
A cluster-randomised trial in Saponé found seasonal chemoprevention given to children up to age 10 nearly halved parasite carriage in 5-to-9-year-olds, though supervised delivery brought no clear gain under age five.
An analysis of 15 years of case data from Altamira, in the Xingu Basin, finds forest edge and local population size — not climate — explained where transmission returned.
WHO and UNICEF estimates put DTP3 coverage at 85% for a second year running. Yellow fever protection sits at 53% in at-risk countries and HPV at 33% in girls, both far below target.
Across 84,348 hospital admissions, 19.8% of children had severe anaemia; as malaria receded the burden moved to older children, and severe anaemia doubled the odds of dying.
A Lancet evaluation of the RTS,S introduction in Ghana, Kenya and Malawi reports a 13% drop in mortality among vaccine-eligible children — achieved with third-dose coverage of 71% and fourth-dose uptake under 40%.
The estimate covers 2000 to 2023 and 108 countries. It is a counterfactual model, not a measured saving, and it lands as the US and other donors debate cutting the disease-specific funding it credits.
Two doses of the long-acting antibody L9LS protected under-fives in a high-transmission area, but researchers say a higher dose is likely needed for stronger cover.
Fourteen months after an undiagnosed febrile outbreak alarmed the world, sequencing and PCR on 108 patients found no novel pathogen — half had falciparum malaria and many had a respiratory co-infection.
The Eighth Replenishment closed at US$12.64 billion against the US$18 billion its own Investment Case tied to 23 million lives saved and 400 million infections prevented by 2029.
The Lancet Global Health paper that produced this month's headline number also produced a larger one: 22.6 million additional deaths by 2030 if defunding deepens. The distinction matters more than the figure.
Washington intends to provide up to $792 million over five years. Malawi commits the rest — and the money is meant to flow through the government rather than NGOs.
The year-end immunization summary reports 88% fewer measles deaths since 2000, malaria vaccine in 24 African countries, and 25 years without wild polio in the Western Pacific.
WHO's World malaria report counts 282 million cases and 610,000 deaths for 2024. The US$3.9 billion spent was under half the US$9.3 billion the global strategy called for.
In a 400-pair trial in Uganda where every family already had a bed net, insecticide-treated wraps reduced clinical malaria in infants from 2.14 to 0.73 cases per 100 person-weeks.
IHME's annual accounting puts development assistance for health at less than half its 2021 peak, with no recovery forecast to 2030. A companion model estimates what that means for tuberculosis.